Group 1 - BioCardia, Inc. has regained full compliance with Nasdaq Capital Market's Listing Requirements as of September 17, 2024, following a decision by the Hearing Panel on May 13, 2024 [1] - The company demonstrated compliance with Listing Rule 5550(b)(1), allowing it to continue listing its securities on the Nasdaq Stock Market [1] - This compliance follows the company's successful efforts to improve its balance sheet, including raising new capital for the development of therapeutic candidates and advancing approved products [1] Group 2 - Recent developments include FDA approval for the CardiAMP® Cell Therapy Heart Failure II protocol amendment, allowing for a more tailored treatment plan for patients [2] - The University of Wisconsin has treated the last roll-in patient in the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial, indicating progress in clinical trials [2] - BioCardia secured FDA market clearance for its Morph® DNA™ product family and closed a $7.2 million financing to support ongoing efforts [2] Group 3 - BioCardia is a global leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with its main product platforms being CardiAMP® and CardiALLO™ cell therapies [3] - The company has three clinical stage product candidates in development, supported by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms [3]
BioCardia Regains Full Compliance with Nasdaq Listing Requirements